Small Increases in Insulin Inhibit Hepatic Glucose Production Solely Caused by an Effect on Glycogen Metabolism
- Dale S. Edgerton1,
- Sylvain Cardin1,
- Maya Emshwiller1,
- Doss Neal1,
- Visvanathan Chandramouli2,
- William C. Schumann2,
- Bernard R. Landau2,
- Luciano Rossetti3 and
- Alan D. Cherrington1
- 1Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee
- 2Department of Medicine and Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio
- 3Diabetes Research and Training Center and Division of Endocrinology, Albert Einstein College of Medicine, Bronx, New York
Abstract
Based on our earlier work, a 2.5-fold increase in insulin secretion should completely inhibit hepatic glucose production through the hormone’s direct effect on hepatic glycogen metabolism. The aim of the present study was to test the accuracy of this prediction and to confirm that gluconeogenic flux, as measured by three independent techniques, was unaffected by the increase in insulin. A 40-min basal period was followed by a 180-min experimental period in which an increase in insulin was induced, with euglycemia maintained by peripheral glucose infusion. Arterial and hepatic sinusoidal insulin levels increased from 10 ± 2 to 19 ± 3 and 20 ± 4 to 45 ± 5 μU/ml, respectively. Net hepatic glucose output decreased rapidly from 1.90 ± 0.13 to 0.23 ± 0.16 mg · kg−1 · min−1. Three methods of measuring gluconeogenesis and glycogenolysis were used: 1) the hepatic arteriovenous difference technique (n = 8), 2) the [14C]phosphoenolpyruvate technique (n = 4), and 3) the 2H2O technique (n = 4). The net hepatic glycogenolytic rate decreased from 1.72 ± 0.20 to −0.28 ± 0.15 mg · kg−1 · min−1 (P < 0.05), whereas none of the above methods showed a significant change in hepatic gluconeogenic flux (rate of conversion of phosphoenolpyruvate to glucose-6-phosphate). These results indicate that liver glycogenolysis is acutely sensitive to small changes in plasma insulin, whereas gluconeogenic flux is not.
Footnotes
-
Address correspondence and reprint requests to Dale Edgerton, Department of Molecular Physiology and Biophysics, 702 Light Hall, Vanderbilt University School of Medicine, Nashville, TN 37232. Email: dale.edgerton{at}vanderbilt.edu.
Received for publication 28 June 2000 and accepted in revised form 4 May 2001.
AV, arteriovenous; G6P, glucose-6-phosphate; Hep GLY; hepatic release of glycogenolytically derived glucose; Hep GNG; hepatic release of gluconeogenically derived glucose; HGP, hepatic glucose production; HGR, hepatic glucose release; HGU, hepatic glucose uptake; ID, internal diameter; NEFA, nonesterified fatty acid; NHGO, net hepatic glucose output; NHLO, net hepatic lactate output; PEP, phosphoenolpyruvate; PEPCK, PEP carboxykinase; Ra, endogenous glucose production; Rd, endogenous glucose utilization; TGO, total glucose output; UDPG, uridinediphosphoglucose.














